Kaloyannidis P, Hertzberg M, Webb K, et al. - Researchers compared brentuximab vedotin (BV) with salvage chemotherapy as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL) patients following autologous stem cell transplantation (ASCT) in this literature-based analysis with an indirect treatment comparison. This inquiry was held to support a reimbursement submission for BV to the Australian Pharmaceutical Benefits Advisory Committee. Using four data sources, they analyzed individual patient data retrospectively. Findings revealed improvements in both clinical response and overall survival in correlation with the use of BV as first salvage therapy in cHL patients relapsing or progressing after ASCT. An incremental improvement of 22% in overall response rate was provided by BV vs salvage chemotherapy. For BV vs salvage chemotherapy, the estimated 5-year overall survival rates were 92·2% vs 30·5%, and 5-year progression-free survival rates were 32·2% vs 3·2%, respectively. This study offers encouraging outcomes that may support informed clinical management and funding decisions for the first salvage of cHL patients showing recurrence following ASCT.